While much research has focused on the mechanisms of acquired drug resistance during B-ALL treatment, our recent study highlights the importance of non-genomic GC responses in B-ALL, where GCs paradoxically induce their own resistance by activating CXCR4 signaling, which in turn activates the PLC pathway [19]. This evidence concerns the gene HSPG2 and precursor B-cell acute lymphoblastic leukemia.